Irinotecan Amarox

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Amarox, is a topoisomerase I inhibitor presented as an injectable formulation for intravenous use. It is employed in the treatment of metastatic and advanced colorectal cancer in adult patients and is typically given as part of combination chemotherapy protocols overseen by oncology specialists.

GNH USA supplies Irinotecan Amarox as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and specialty pharmacies worldwide with full regulatory documentation and quality assurance.

Irinotecan Amarox is a topoisomerase I inhibitor used in colorectal cancer chemotherapy.

Metastatic colorectal cancer: contributes to prolonged overall survival and disease stabilization when combined with other cytotoxic agents. Advanced colorectal cancer: achieves tumor size reduction and symptomatic improvement as part of first‑line or second‑line chemotherapy regimens. Colorectal adenocarcinoma with unresectable lesions: facilitates down‑staging of tumors to enable potential surgical intervention in selected patients. Rectal cancer with distant metastasis: offers systemic disease control alongside radiotherapy in multidisciplinary approaches.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal medication. - Nausea and vomiting: may be managed with standard antiemetics. - Neutropenia: decreased white blood cell count increasing infection risk. - Alopecia: hair loss that is usually reversible after treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring immediate medical attention. - Severe colitis or intestinal perforation: life‑threatening complications of diarrhea. - Elevated liver enzymes: indicating hepatic toxicity that may necessitate dose adjustment.

Prior to initiating Irinotecan Amarox, clinicians should observe several safety measures to minimize toxicity.

- Baseline blood counts: obtain complete blood count to assess neutrophil levels before treatment. - Liver function monitoring: evaluate hepatic enzymes regularly because metabolism depends on liver activity. - Hydration status: ensure adequate fluid intake to reduce risk of severe diarrhea. - Concomitant myelosuppressive drugs: avoid or adjust doses of other agents that suppress bone marrow. - CYP3A4 and UGT1A1 interactions: review patient medications for strong inhibitors or inducers that affect Irinotecan metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Irinotecan may interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise SN‑38 levels and heighten toxicity. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): may reduce SN‑38 clearance leading to severe neutropenia. - Concurrent myelosuppressive chemotherapy: increases risk of profound bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug exposure and reduce effectiveness. - Warfarin: Irinotecan can affect anticoagulation control, requiring INR monitoring. - Diuretics: may exacerbate dehydration from diarrhea, necessitating fluid balance assessment.